Home › Funds › SB INVESTMENT ADVISERS (UK) LTD › VIR
SB INVESTMENT ADVISERS (UK) LTD position in VIR
VIR BIOTECHNOLOGY INC · Health Care
SB INVESTMENT ADVISERS (UK) LTD reported holding 10,948,093 shares of VIR (VIR BIOTECHNOLOGY INC) in its Q3 2026 13F filing — a position valued at US$122.4M, representing 1.99% of its reported portfolio and ranking #5 among its reported holdings. SB INVESTMENT ADVISERS (UK) LTD has disclosed VIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How SB INVESTMENT ADVISERS (UK) LTD's VIR position evolved
SB INVESTMENT ADVISERS (UK) LTD first disclosed a stake in VIR in Q3 2023 at 16,684,041 shares (US$156.3M). The position peaked in Q1 2024 at 16,684,041 shares, worth US$169.0M. Across 13 filings, SB INVESTMENT ADVISERS (UK) LTD increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 10,948,093 shares valued at US$122.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 16.68M | $156.33M | New |
| Q4 2023 | 16.68M | $167.84M | Hold |
| Q1 2024 | 16.68M | $169.01M | Hold |
| Q2 2024 | 16.68M | $148.49M | Hold |
| Q3 2024 | 16.68M | $124.96M | Hold |
| Q4 2024 | 16.68M | $122.46M | Hold |
| Q1 2025 | 16.68M | $108.11M | Hold |
| Q2 2025 | 16.68M | $84.09M | Hold |
| Q3 2025 | 16.68M | $95.27M | Hold |
| Q4 2025 | 13.12M | $79.10M | Reduce |
| Q1 2026 | 10.95M | $98.09M | Reduce |
| Q2 2026 | 10.95M | $111.56M | Hold |
| Q3 2026 | 10.95M | $122.40M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VIR and 13F data
VIR (VIR BIOTECHNOLOGY INC) is a Health Care company. 37 other funds we track also report a position in VIR — the largest reported positions include ARCH Venture Management, LLC (US$141.9M), GSK plc (US$95.6M), MPM BioImpact LLC (US$31.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VIR
- ARCH Venture Management, LLC 12.69M sh · $141.92M · Q3 2026
- GSK plc 8.55M sh · $95.60M · Q3 2026
- MPM BioImpact LLC 2.81M sh · $31.41M · Q3 2026
- ADAR1 Capital Management, LLC 2.16M sh · $24.14M · Q3 2026
- Saturn V Capital Management LP 2.04M sh · $22.81M · Q3 2026
- Sio Capital Management, LLC 873.38K sh · $9.76M · Q3 2026
- GordonMD Global Investments LP 803.55K sh · $8.98M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 578.70K sh · $6.47M · Q3 2026
More on SB INVESTMENT ADVISERS (UK) LTD
FAQ
How long has SB INVESTMENT ADVISERS (UK) LTD held VIR?
SB INVESTMENT ADVISERS (UK) LTD has disclosed VIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SB INVESTMENT ADVISERS (UK) LTD's current position in VIR?
As of Q3 2026, SB INVESTMENT ADVISERS (UK) LTD holds 10.95M shares of VIR (VIR BIOTECHNOLOGY INC), valued at $122.40M, representing 1.99% of its reported portfolio and ranking #5.
Has SB INVESTMENT ADVISERS (UK) LTD been buying or selling VIR?
In the latest 13F filing (Q3 2026), SB INVESTMENT ADVISERS (UK) LTD held unchanged its position in VIR. The position peaked in Q1 2024 at 16.68M shares.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, GSK plc, MPM BioImpact LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.